The HDSA RESEARCH WEBINAR: The Roche/Genentech GENERATION HD2
Study of Tominersen; a new clinical trial that is now open to folks with Huntington’s disease (HD) who meet the criteria. The webinar is worth watching. Tominersen is an antisense therapy that acts by reducing the production of all forms of the huntingtin protein (HTT), including its mutated variant (mHTT), which is believed to be the main cause of HD.
Info on the study:
-Adults 25-50 years of age (early stage of HD)
-360 people in the study
-Clinical trial locations will be in 15 countries; more than 1 in US
-16 month treatment period
Go to: http://gene.com/patients/clinical-trial-information to read about the Tominersen study and how to get involved. Or ClinicalTrials.gov or signup for HDTrialFinder
No Comments